UBS AM’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.22K | Hold |
146
| – | – | ﹤0.01% | 3599 |
|
|
2026
Q1 | $1.21K | Sell |
146
-148
| -50% | -$1.53K | ﹤0.01% | 3660 |
|
|
2025
Q4 | $3.63K | Buy |
+294
| New | +$3.15K | ﹤0.01% | 3037 |
|
|
2023
Q4 | – | Sell |
-57,653
| Closed | -$196K | – | 2559 |
|
|
2023
Q3 | $196K | Buy |
57,653
+12,507
| +28% | +$69.3K | ﹤0.01% | 2519 |
|
|
2023
Q2 | $468K | Hold |
45,146
| – | – | ﹤0.01% | 2349 |
|
|
2023
Q1 | $468K | Sell |
45,146
-3,098
| -6% | -$37.4K | ﹤0.01% | 2349 |
|
|
2022
Q4 | $570K | Sell |
48,244
-2,539
| -5% | -$39.3K | ﹤0.01% | 2128 |
|
|
2022
Q3 | $1.07M | Sell |
50,783
-1,806
| -3% | -$50.3K | ﹤0.01% | 1927 |
|
|
2022
Q2 | $1.63M | Sell |
52,589
-10,081
| -16% | -$344K | ﹤0.01% | 1711 |
|
|
2022
Q1 | $2.57M | Buy |
62,670
+12,146
| +24% | +$536K | ﹤0.01% | 1666 |
|
|
2021
Q4 | $2.2M | Sell |
50,524
-7,686
| -13% | -$348K | ﹤0.01% | 1829 |
|
|
2021
Q3 | $2.91M | Sell |
58,210
-828
| -1% | -$50.1K | ﹤0.01% | 1661 |
|
|
2021
Q2 | $3.72M | Sell |
59,038
-7,368
| -11% | -$473K | ﹤0.01% | 1520 |
|
|
2021
Q1 | $6.17M | Sell |
66,406
-4,395
| -6% | -$450K | ﹤0.01% | 1256 |
|
|
2020
Q4 | $6.34M | Buy |
70,801
+4,414
| +7% | +$405K | ﹤0.01% | 1202 |
|
|
2020
Q3 | $6.86M | Sell |
66,387
-1,021
| -2% | -$110K | ﹤0.01% | 1050 |
|
|
2020
Q2 | $5.33M | Sell |
67,408
-6,479
| -9% | -$483K | ﹤0.01% | 1091 |
|
|
2020
Q1 | $4.28M | Buy |
73,887
+5,068
| +7% | +$292K | ﹤0.01% | 1100 |
|
|
2019
Q4 | $3.71M | Sell |
68,819
-16,418
| -19% | -$890K | ﹤0.01% | 1320 |
|
|
2019
Q3 | $4.46M | Buy |
85,237
+6,078
| +8% | +$283K | ﹤0.01% | 1253 |
|
|
2019
Q2 | $3.82M | Buy |
79,159
+27,813
| +54% | +$1.33M | ﹤0.01% | 1296 |
|
|
2019
Q1 | $2.59M | Buy |
51,346
+1,569
| +3% | +$92.5K | ﹤0.01% | 1396 |
|
|
2018
Q4 | $2.95M | Buy |
49,777
+3,230
| +7% | +$208K | ﹤0.01% | 1277 |
|
|
2018
Q3 | $3.06M | Sell |
46,547
-60
| -0.1% | -$3.5K | ﹤0.01% | 1327 |
|
|
2018
Q2 | $2.35M | Buy |
46,607
+3,545
| +8% | +$185K | ﹤0.01% | 1427 |
|
|
2018
Q1 | $2.27M | Sell |
43,062
-438,745
| -91% | -$21.9M | ﹤0.01% | 1412 |
|
|
2017
Q4 | $22.4M | Sell |
481,807
-71,713
| -13% | -$3.02M | 0.02% | 713 |
|
|
2017
Q3 | $22.4M | Sell |
553,520
-75,039
| -12% | -$2.71M | 0.02% | 714 |
|
|
2017
Q2 | $21.3M | Sell |
628,559
-30,219
| -5% | -$933K | 0.02% | 720 |
|
|
2017
Q1 | $19.1M | Sell |
658,778
-76,444
| -10% | -$2.33M | 0.02% | 727 |
|
|
2016
Q4 | $24.1M | Buy |
735,222
+2,664
| +0.4% | +$79.9K | 0.03% | 609 |
|
|
2016
Q3 | $23.1M | Buy |
732,558
+46,758
| +7% | +$1.36M | 0.02% | 627 |
|
|
2016
Q2 | $19.3M | Buy |
685,800
+370,847
| +118% | +$14.5M | 0.02% | 688 |
|
|
2016
Q1 | $11.4M | Sell |
314,953
-86,775
| -22% | -$3.07M | 0.01% | 811 |
|
|
2015
Q4 | $16.1M | Sell |
401,728
-182,218
| -31% | -$6.35M | 0.02% | 741 |
|
|
2015
Q3 | $16.6M | Sell |
583,946
-81,392
| -12% | -$2.68M | 0.02% | 737 |
|
|
2015
Q2 | $21.9M | Buy |
665,338
+103,066
| +18% | +$3.2M | 0.02% | 692 |
|
|
2015
Q1 | $16.2M | Buy |
562,272
+90,167
| +19% | +$2.59M | 0.02% | 761 |
|
|
2014
Q4 | $12.9M | Sell |
472,105
-25,564
| -5% | -$609K | 0.01% | 809 |
|
|
2014
Q3 | $10.6M | Buy |
497,669
+135,863
| +38% | +$3.11M | 0.01% | 821 |
|
|
2014
Q2 | $8.13M | Sell |
361,806
-246,688
| -41% | -$5.75M | 0.01% | 914 |
|
|
2014
Q1 | $15.4M | Sell |
608,494
-5,771
| -0.9% | -$146K | 0.02% | 720 |
|
|
2013
Q4 | $14.1M | Sell |
614,265
-2,892
| -0.5% | -$60.3K | 0.02% | 732 |
|
|
2013
Q3 | $11.8M | Buy |
617,157
+55,574
| +10% | +$992K | 0.01% | 761 |
|
|
2013
Q2 | $8.1M | Buy |
+561,583
| New | +$8.13M | 0.01% | 833 |
|
Other funds holding EBS
OHA
UBS AM's EBS Position: Q2 2026 in Review
UBS AM held its Emergent Biosolutions (EBS) position steady in Q2 2026 at 146 shares worth $1.22K. The position accounts for ﹤0.01% of the portfolio, ranked #3599.
UBS AM first reported a position in EBS in Q2 2013 and has held it in 45 quarters since. The position peaked at $24.1M in Q4 2016. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.
- UBS AM held 146 shares of Emergent Biosolutions worth $1.22K as of Q2 2026.
- UBS AM left its Emergent Biosolutions share count unchanged in Q2 2026.
- Emergent Biosolutions made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3599 holding.
- UBS AM first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 45 quarters since.
- UBS AM's Emergent Biosolutions position peaked at $24.1M in Q4 2016.
- 195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.